Optomed Oyj 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Juho Himberg

최고 경영자

€64.0k

총 보상

CEO 급여 비율	81.3%
CEO 임기	1.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Juho Himberg 의 보수는 Optomed Oyj 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-€6m
Jun 30 2024	n/a	n/a	-€5m
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

보상 대 시장: Juho 의 총 보상 ($USD 67.05K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 472.15K ).

보상과 수익: Juho 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Juho Himberg (54 yo)

1.1yrs

테뉴어

€64,000

보상

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

리더십 팀

이름	위치	테뉴어	보상	소유권
Juho Himberg	Chief Executive Officer	1.1yrs	€64.00k	데이터 없음
Seppo Kopsala	Founder	20.8yrs	€156.00k	데이터 없음
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.8yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 36U0 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Seppo Makinen	Independent Director	5.8yrs	€19.00k	0.062% € 48.8k
Reijo Tauriainen	Independent Director	5.8yrs	€19.00k	0.078% € 61.1k
Catherine Calarco	Independent Director	1.5yrs	€19.00k	0.017% € 13.6k
Petri Salonen	Chairman of the Board	18.8yrs	€114.00k	0.083% € 64.7k
Ty Lee	Independent Director	1.5yrs	€19.00k	0.017% € 13.6k
Anna Tenstam	Independent Director	4.4yrs	€19.00k	0.037% € 28.8k
Robert Chang	Member of International Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Nina Hautala	Member of International Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Dan Milea	Member of International Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Tunde Peto	Member of International Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Daniel Ting	Member of International Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 36U0 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Optomed Oyj 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Optomed Oyj, Annual General Meeting, May 09, 2025

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Recent updates

Optomed plc Raises Earnings Guidance for the Full Year 2024

Optomed plc Raises Earnings Guidance for the Full Year 2024

No longer forecast to breakeven

Third quarter 2024 earnings released: €0.087 loss per share (vs €0.027 loss in 3Q 2023)

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Market cap size

Optomed Oyj, Annual General Meeting, May 09, 2025

Second quarter 2024 earnings released: €0.10 loss per share (vs €0.084 loss in 2Q 2023)

Optomed Oyj Reaffirms Revenue Guidance for the Year 2024

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Forecast to breakeven in 2026

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Full year 2023 earnings released: €0.27 loss per share (vs €0.37 loss in FY 2022)

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Optomed Oyj Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: €0.027 loss per share (vs €0.097 loss in 3Q 2022)

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.096 loss in 2Q 2022)

Optomed Oyj, Annual General Meeting, May 10, 2024

New minor risk - Share price stability

New minor risk - Share price stability

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

First quarter 2023 earnings released: €0.076 loss per share (vs €0.10 loss in 1Q 2022)

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: €0.37 loss per share (vs €0.32 loss in FY 2021)

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

High number of new and inexperienced directors

Third quarter 2022 earnings released: €0.097 loss per share (vs €0.062 loss in 3Q 2021)

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings released: €0.096 loss per share (vs €0.065 loss in 2Q 2021)

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령